Shares of Eli Lilly (LLY) are pulling back after hitting an all-time high. The pharmaceutical company’s stock has dropped 4% in the past week after reaching a record intraday high of $1,292.65. LLY stock had been trending higher after the company delivered blowout financial results for this year’s second quarter. Year-to-date, Eli Lilly’s shares have gained 11%.
LLY shares closed at a record high of $1,280.34 on Aug. 19 after the company reported strong quarterly financial results that showed accelerating sales of its weight-loss drugs. But over the past week, the stock has traded in a range of $1,180.01 to $1,235.775. The current pullback looks like a normal consolidation after a strong run to fresh highs.

Eli Lilly’s earnings per share. Source: The Fly
Lowering Drug Costs
Separately, Eli Lilly has released findings from an analysis that shows its Zepbound weight-loss medication is helping to lower healthcare costs in the U.S. Elderly patients taking the obesity drug were found to make fewer trips to the hospital and emergency room than overweight people who are not on Zepbound. The findings were published in the academic journal “Diabetes, Obesity and Metabolism.”
Specifically, the analysis found that elderly patients taking Zepbound saw their monthly healthcare costs come in 15% lower after half a year, translating to roughly $181 in savings per patient each month. That advantage grew even larger by the one-year mark, reaching an estimated $607 in monthly per-patient savings, or about 38% below what untreated patients spent on heathcare.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 20 Wall Street analysts. That rating is based on 18 Buy and two Hold recommendations issued in the past three months. The average LLY price target of $1,375.78 implies 12% upside from current levels.



